Skip to main content
SpringerLink
Log in

Etanercept

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1235 Accesses

Abstract

Etanercept (Enbrel®, Immunex, Amgen, and Pfizer) is a fusion protein combining the Fc domain of human IgG1 to the extracellular portion of the tumor necrosis factor receptor-2 (TNFR2, p75). TNFR2 binds to soluble TNFs (TNFα, TNFβ -LTα-), thus blocking the interaction with their natural receptors and interrupting the activation of TNF-related proinflammatory pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    JRA (commonly used in USA) and JCA (used in EU) are older terms replaced and included in JIA, which also encompasses other forms of idiopathic arthritis in childhood and adolescence. JRA includes systemic onset (sJIA), oligo/pauci-articular (oJIA), and polyarticular (PIJA or simply JIA) subgroups of arthritis. ERA and PsA refer to other clinical subgroups linked to AS and to Ps, respectively. Therefore, JIA describes a clinically heterogeneous group of arthritides.

References

  1. Etanercept (Enbrel®) BLA 98-0286 Clinical Review for RA, FDA, Dec 1998

    Google Scholar 

  2. Etanercept (Enbrel®) BLA 98-0286 Clinical Review for JRA, FDA, Nov 1998

    Google Scholar 

  3. Etanercept (Enbrel®) BLA 103795/5123 Medical Review for AS, FDA, July 2003

    Google Scholar 

  4. Etanercept (Enbrel®) BLA 103795/5102 Medical Review for PsA, FDA, Aug 2003

    Google Scholar 

  5. Etanercept (Enbrel®) WC500027358 Scientific Discussion for RA, EMEA Oct 2004

    Google Scholar 

  6. Etanercept (Enbrel®) WC500027362 Assessment Report for pediatric Ps, EMEA, Nov 2008

    Google Scholar 

  7. Etanercept (Enbrel®) WC500113064 Assessment Report for pediatric Ps, EMEA, Sept 2011

    Google Scholar 

  8. Etanercept (Enbrel®) WC50011281 Assessment Report for JIA. EMEA, June 2012

    Google Scholar 

  9. Etanercept (Enbrel®) Prescribing Information, Pfizer 2012

    Google Scholar 

  10. Etanercept (Enbrel®) WC500027361 EPAR Annex I, EMEA 2013

    Google Scholar 

  11. Etanercept (Enbrel®) WC500137356, WC500137357, WC500137358, WC500137359, Assessment Reports (Ps, JRA, and RA), EMEA, Jan 2013

    Google Scholar 

  12. Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 117:244–279

    Article  PubMed  CAS  Google Scholar 

  13. Horiuki T, Mitoma H, Harashima S et al (2010) Transmembrane TNFα: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228

    Article  Google Scholar 

  14. Edwards CK, Green JS, Volk HD et al (2012) Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol. doi:10.3389/fimmu.2012.00366

    Google Scholar 

  15. Konsta M, Bamias G, Tektonidou MG et al (2012) Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology. doi:10.1093/rheumatology/kes316

    PubMed  Google Scholar 

  16. Garcês S, Demengeot J, Benito-Garcia E (2012) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 0:1–9. doi:10.1136/annrheumdis-2012-202220

    Google Scholar 

  17. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56:3248–3252

    Article  PubMed  CAS  Google Scholar 

  18. Minden K, Niewerth M, Zink A et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 51:1407–1415

    Article  PubMed  CAS  Google Scholar 

  19. Jobanputra P, Maggs F, Deeming A et al (2012) A randomized efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2:e001395

    Article  PubMed  Google Scholar 

  20. Song IH, Hermann KG, Haibel H et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48 week randomized controlled trial. Ann Rheum Dis 70:590–596

    Article  PubMed  CAS  Google Scholar 

  21. Smolen JS, Nash P, Durez P et al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet Online. doi:10.1016/S0140-6736(12)61811

    Google Scholar 

  22. Cantini F, Niccoli L, Cassarà E et al (2013) Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biol Targets Ther 7:1–6

    Article  CAS  Google Scholar 

  23. Brezinski EA, Armstrong AW (2012) Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE 7:e33486

    Article  PubMed  CAS  Google Scholar 

  24. Esposito M, Giunta A, Mazzotta A et al (2012) Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. doi:10.1159/000345623

    PubMed  Google Scholar 

  25. Kim HY, Hsu PN, Barba M et al (2012) Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 15:188–196

    Article  PubMed  CAS  Google Scholar 

  26. Barrientos N, García-Sánchez S, Domínguez JD (2012) Lichenoid eruption induced by etanercept. Dermatol Online J 18:15

    PubMed  Google Scholar 

  27. Lamrock E, Brown P (2012) Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australas J Dermatol 53:e87–e90

    Article  PubMed  Google Scholar 

  28. Fonollosa A, Artaraz J, Martinez-Berriotxoa A et al (2012) Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm. doi:10.3109/09273948.2011.623212

    PubMed  Google Scholar 

  29. Hawryluk EB, Linskey KR, Duncan LM et al (2012) Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cut Path 39:481–492

    Article  Google Scholar 

  30. Scmidt E, Wetter DA, Ferguson SB et al (2012) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo clinic experience, 1998 to 2010. J Am Acad Dermatol. doi:10.1016/j.jaad.2011.05.038

    Google Scholar 

  31. Martinez Santana V, Izquierdo Navarro M, Calleja Hernandez MA et al (2012) Severe pancytopenia following etanercept administration in rheumatoid arthritis. Intern J Rheum Dis 15:e78–e79

    Article  Google Scholar 

  32. Khaja M, Menon L, Niazi M et al (2012) Diffuse alveolar hemorrhage and acute respiratory distress syndrome during treatment of rheumatoid arthritis with etanercept. J Bronchol Interv Pulmonol 19:228–231

    Article  Google Scholar 

  33. Rolle AS, Zimmermann B, Poon SH (2013) Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol. doi:10.1097/RHU.0b013e3182863027

    PubMed  Google Scholar 

  34. Sadlier M, Connaghan G, Kirby B (2012) Acute myeloid leukemia presenting with cutaneous infiltrates in a patient receiving etanercept for chronic lymphocytic vasculitis. J Am Acad Dermatol. doi:10.1016/j.jaad.2012.03.037

    Google Scholar 

  35. Mrabet D, Selmi A, Filali A et al (2012) Maladie de Crohn induite par l’étanercept: à propos d’une nouvelle observation. Rev Med Liege 67:619–622

    PubMed  CAS  Google Scholar 

  36. Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD et al (2010) Emergence of Crohn’s disease in juvenile arthritis during treatment with etanercept: a casual link or a mere coincidence? J Gastrointest Liver Dis 19:342

    Google Scholar 

  37. Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31:116–121

    Google Scholar 

  38. Gaujoux C, Giampietro C, Gaujoux T et al (2012) Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 39:233–239

    Article  PubMed  Google Scholar 

  39. Herrinton LJ, Liu L, Chen L et al (2012) Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf 21:1311–1320

    Article  PubMed  CAS  Google Scholar 

  40. Simard JF, Noevius M, Askling J (2012) Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Drug-specific comparisons in the Swedish Biologics Registry. Arthritis Rheum 64:3502–3510

    Google Scholar 

  41. Karampetsou MP, Liossis SNC, Sfikakis PP (2010) TNF-α antagonists beyond approved indications: stories of success and prospects for the future. Q J Med 103:917–928

    Article  CAS  Google Scholar 

  42. Anink J, Otten MH, Prince FHM et al (2012) Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and biologicals in children register. Rheumatology. doi:10.1093/rheumatology/kes373

    PubMed  Google Scholar 

  43. Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61–70

    Article  PubMed  CAS  Google Scholar 

  44. Watanabe S, Alzawa-Yashiro T, Tsuruga K et al (2012) A young girl with refractory intestinal Behçet’s disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int. doi:10.1007/s00296-012-2628-5

  45. Guedes S, Moreira A, Menezes N et al (2012) Treatment of thalidomide resistant pyoderma gangrenosum with etanercept. Acta Dermatovenereol Croat 20:175–180

    CAS  Google Scholar 

  46. Van Rappard DC, Limpens J, Mekkes JR (2012) The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review. J Dermatol Treat. doi:10.3109/09546634.2012.674193

    Google Scholar 

  47. Kim NH, Torchia D, Rouhani P et al (2011) Tumor necrosis-α in vitiligo: direct correlation between tissue levels and clinical parameters. Cutan Ocul Toxicol 30:225–227

    Article  PubMed  CAS  Google Scholar 

  48. Nin M, Tokunaga D, Ishii N et al (2013) Case of coexisting psoriasic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 40:55–56

    Article  PubMed  Google Scholar 

  49. Silva F, Cisternas M, Specks U (2012) TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis. Curr Rheumatol Rep 14:501–508

    Article  PubMed  CAS  Google Scholar 

  50. Amato AA and The Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427–436

    Article  Google Scholar 

  51. Tobinik E (2011) Rapid improvement of chronic stroke deficits after perispinal etanercept. Three consecutive cases. CNS Drugs 25:145–156

    Article  Google Scholar 

  52. Javed Q, Murtaza I (2013) Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. doi:10.1016/j.hlc.2012.12.002

    PubMed  Google Scholar 

  53. Aaron SD, Vandemheen KL, Maltais F et al (2013) TNF-α antagonists for acute exacerbations of COPD: a randomized double-blind controlled trial. Thorax 68:142–148

    Article  PubMed  Google Scholar 

  54. Akgul O, Kilic E, Kilic G et al (2012) Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci. doi: 10.1097/MAJ.0b013e318277083b

  55. Haraoui B, Krelenbaum M (2009) Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 39:176–181

    Article  PubMed  CAS  Google Scholar 

  56. Bes C, Yazici A, Soy M (2012) Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis. Rheumatol Int. doi:10.1007/s00296-012-2539-5

    Google Scholar 

  57. Jančić I, Arsenović-Ranin N, Sefic-Bulilica M et al (2012) 174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-012-2586-y

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 65 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Etanercept. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_45

Download citation

Publish with us

Policies and ethics

Search

Navigation